Clinical Prescribing System Resources for transitioning patients from Levemir® (insulin detemir)
This site and associated resources have been funded by Novo Nordisk UK and developed in conjunction with Oberoi Consulting. They are intended for Healthcare Professionals (HCPs) and Other Relevant Decision Makers (ORDMs) who have population level decision making capability for their Healthcare Organisation. Clinical discretion should be exercised by the HCP to determine the best management plan for their patients.
The discontinuation of Levemir® in the UK poses a significant burden to the NHS of identifying and reviewing Levemir® patients prior to final discontinuation which is anticipated to be at the end of 2026.
To support the NHS through this transition, Novo Nordisk UK (NNUK) have developed a package of support consisting of downloadable tools that aim to assist healthcare organisations (HCOs) with the identification of patients currently using Levemir®.
These downloadable resources are available for all the main clinical prescribing systems across the UK, EMIS Web, SystmOne and Vision. They consist of predefined patient record searches and system alerts to support identification of those patients currently receiving Levemir®.
The predefined searches have been aligned to the clinical groups highlighted within the Discontinuation of Levemir® (insulin detemir): Joint guidance from ABCD and PCDO Society1. Novo Nordisk UK have had no involvement in the development of this guideline.
Compatible with EMIS Web, SystmOne and Vision.
Integrated clinical prescribing system resources that involve no external software or processing of patient identifiable data.
SEARCHES
Identify patients prescribed Levemir® using predefined searches.
ALERTS
Activated when accessing electronic records of patients' prescribed Levemir®.
The predefined searches are intended to help identify those patients currently receiving Levemir® and require transition to a suitable alternative.
Pop-up system alerts are also available to integrate within the clinical prescribing system, aligned to the predefined search rationale, helping to flag patients at the point of opening of a patient record during a consultation.
Click here to view the Search and Alert Rationale
Any interaction you may have with Oberoi Technical Support will be completely independent of NNUK, and no details of your call/email will be shared with NNUK.
Adverse Event Reporting
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse Events should also be reported to Novo Nordisk UK (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.
1) Primary Care Diabetes & Obesity Society (PCDOS) and Association of British Clinical Diabetologists (ABCD). Discontinuation of Levemir® (insulin detemir) FlexPen® and Penfill® Clinical Guideline. Aug 2025. Available from https://www.pcdosociety.org/guidance/levemir-discontinuation [last accessed: November 2025]
Job code: UK25LV00017 |
Date of Prep: Nov 2025